JP2004531484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531484A5 JP2004531484A5 JP2002565984A JP2002565984A JP2004531484A5 JP 2004531484 A5 JP2004531484 A5 JP 2004531484A5 JP 2002565984 A JP2002565984 A JP 2002565984A JP 2002565984 A JP2002565984 A JP 2002565984A JP 2004531484 A5 JP2004531484 A5 JP 2004531484A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- substituted
- pyridyl
- phenyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 —OR 3 Chemical group 0.000 claims 640
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 136
- 125000001424 substituent group Chemical group 0.000 claims 116
- 150000001875 compounds Chemical class 0.000 claims 107
- 125000005843 halogen group Chemical group 0.000 claims 90
- 125000000623 heterocyclic group Chemical group 0.000 claims 89
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 65
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims 46
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 45
- 125000005956 isoquinolyl group Chemical group 0.000 claims 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 39
- 125000004076 pyridyl group Chemical group 0.000 claims 38
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 37
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 34
- 229910052799 carbon Inorganic materials 0.000 claims 33
- 125000001041 indolyl group Chemical group 0.000 claims 33
- 125000005493 quinolyl group Chemical group 0.000 claims 33
- 125000001188 haloalkyl group Chemical group 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 125000002098 pyridazinyl group Chemical group 0.000 claims 32
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 32
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 30
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 28
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 28
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 27
- 125000004043 oxo group Chemical group O=* 0.000 claims 27
- 125000001544 thienyl group Chemical group 0.000 claims 27
- 125000002883 imidazolyl group Chemical group 0.000 claims 26
- 125000003226 pyrazolyl group Chemical group 0.000 claims 26
- 125000001624 naphthyl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 23
- 125000005466 alkylenyl group Chemical group 0.000 claims 22
- 125000002541 furyl group Chemical group 0.000 claims 22
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 16
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 15
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 14
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 14
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 14
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 14
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 13
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 11
- 125000000335 thiazolyl group Chemical group 0.000 claims 11
- 125000001425 triazolyl group Chemical group 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 7
- 229960003966 nicotinamide Drugs 0.000 claims 7
- 239000011570 nicotinamide Substances 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 6
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000005469 ethylenyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 6
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 5
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 4
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- WGJHGKUXAFXEQX-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 WGJHGKUXAFXEQX-UHFFFAOYSA-N 0.000 claims 2
- LYFDVPOSCCMOBX-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide hydrochloride Chemical compound Cl.N1=CC=C(C=C1)CNC1=C(C(=O)N)C=CC=N1 LYFDVPOSCCMOBX-UHFFFAOYSA-N 0.000 claims 2
- CUMQTVPKMVNWHU-UHFFFAOYSA-N 2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=CC=N1 CUMQTVPKMVNWHU-UHFFFAOYSA-N 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- RGMHIWWBTDCTFP-UHFFFAOYSA-N 6-chloro-n-(3,4-dichlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(Cl)=CC=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 RGMHIWWBTDCTFP-UHFFFAOYSA-N 0.000 claims 2
- VZOQOTFQDURGAQ-UHFFFAOYSA-N 6-chloro-n-(3-fluorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC1=CC=CC(NC(=O)C=2C(=NC(Cl)=CC=2)NCC=2C=CN=CC=2)=C1 VZOQOTFQDURGAQ-UHFFFAOYSA-N 0.000 claims 2
- DJBWOZWLNICJDD-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=C(Cl)N=C1NCC1=CC=NC=C1 DJBWOZWLNICJDD-UHFFFAOYSA-N 0.000 claims 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 2
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims 2
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- XOGXKXFCJXASMM-UHFFFAOYSA-N n-(2-cyclohexylethyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NCCC1CCCCC1 XOGXKXFCJXASMM-UHFFFAOYSA-N 0.000 claims 2
- OYJAYZAEARMXTP-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OYJAYZAEARMXTP-UHFFFAOYSA-N 0.000 claims 2
- ZLLZCFGMCYCOBQ-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(quinolin-6-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(N=CC=C2)C2=C1 ZLLZCFGMCYCOBQ-UHFFFAOYSA-N 0.000 claims 2
- FUBGESDOASSFLE-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 FUBGESDOASSFLE-UHFFFAOYSA-N 0.000 claims 2
- BYYGTPFQKSTOIQ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 BYYGTPFQKSTOIQ-UHFFFAOYSA-N 0.000 claims 2
- FXKUDTQNLVDDPM-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(F)C(C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FXKUDTQNLVDDPM-UHFFFAOYSA-N 0.000 claims 2
- PWLWXRCABALOJM-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(C)C(F)=C1 PWLWXRCABALOJM-UHFFFAOYSA-N 0.000 claims 2
- GATIRXMKKFCDFM-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 GATIRXMKKFCDFM-UHFFFAOYSA-N 0.000 claims 2
- CQJYAKDFNABDNR-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(2-pyridin-4-ylethylamino)-5-thiophen-3-ylpyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC(C2=CSC=C2)=CN=C1NCCC1=CC=NC=C1 CQJYAKDFNABDNR-UHFFFAOYSA-N 0.000 claims 2
- NOSWLVYNWMYEPM-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 NOSWLVYNWMYEPM-UHFFFAOYSA-N 0.000 claims 2
- PUYKJIDZYZMYNZ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(quinolin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC2=CC=CC=C12 PUYKJIDZYZMYNZ-UHFFFAOYSA-N 0.000 claims 2
- HFBFVZHPVWEKEW-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(quinolin-5-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC2=NC=CC=C12 HFBFVZHPVWEKEW-UHFFFAOYSA-N 0.000 claims 2
- PAKQOXUFEOQJMO-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NC=CC=C1NCC1=CC=NC=C1 PAKQOXUFEOQJMO-UHFFFAOYSA-N 0.000 claims 2
- WDJDWILIGYPHAK-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)pyridine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=NC=C1NCC1=CC=NC=C1 WDJDWILIGYPHAK-UHFFFAOYSA-N 0.000 claims 2
- LXJWXTCBXDALRB-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=C(NCC=2C=CN=CC=2)C=CS1 LXJWXTCBXDALRB-UHFFFAOYSA-N 0.000 claims 2
- VAYFGMAFEDYANQ-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(quinolin-6-ylmethylamino)pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NC=CC=C1NCC1=CC=C(N=CC=C2)C2=C1 VAYFGMAFEDYANQ-UHFFFAOYSA-N 0.000 claims 2
- DROLXAIBBJVFAX-UHFFFAOYSA-N n-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=C1C(=O)NC=2C=CC(Cl)=CC=2)=CN=C1NCC1=CC=NC=C1 DROLXAIBBJVFAX-UHFFFAOYSA-N 0.000 claims 2
- IUVWAGKDBBJAOZ-UHFFFAOYSA-N n-(4-chlorophenyl)-6-methyl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(C)=CC=C1C(=O)NC1=CC=C(Cl)C=C1 IUVWAGKDBBJAOZ-UHFFFAOYSA-N 0.000 claims 2
- IPXMIRXLYKKBFL-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 IPXMIRXLYKKBFL-UHFFFAOYSA-N 0.000 claims 2
- BDAZNAIKZSBCMI-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 BDAZNAIKZSBCMI-UHFFFAOYSA-N 0.000 claims 2
- KHNJHPHQHJEOJW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(1-methylpiperidin-4-yl)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C3CCN(C)CC3)(C)C)=CC=2)=C1 KHNJHPHQHJEOJW-UHFFFAOYSA-N 0.000 claims 2
- XRYRSTQEFURRFF-UHFFFAOYSA-N n-phenyl-3-(pyridin-4-ylmethylamino)thiophene-2-carboxamide Chemical compound S1C=CC(NCC=2C=CN=CC=2)=C1C(=O)NC1=CC=CC=C1 XRYRSTQEFURRFF-UHFFFAOYSA-N 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 1
- XYOVRYLVCDCUPA-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)-n-[3,3-dimethyl-1-[(1-methylpiperidin-4-yl)methyl]-2h-indol-6-yl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=C4CCOC4=CC=3)=CC=C2C(C)(C)C1 XYOVRYLVCDCUPA-UHFFFAOYSA-N 0.000 claims 1
- YNIVBHYQUVVEDL-UHFFFAOYSA-N 2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(OCC2)C2=C1 YNIVBHYQUVVEDL-UHFFFAOYSA-N 0.000 claims 1
- LLTSIWYJZUHBQZ-UHFFFAOYSA-N 2-(2-pyridin-3-ylethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=NC=CC=2)=C1 LLTSIWYJZUHBQZ-UHFFFAOYSA-N 0.000 claims 1
- KBWQJCSCFQLMCD-UHFFFAOYSA-N 2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 KBWQJCSCFQLMCD-UHFFFAOYSA-N 0.000 claims 1
- YMRSATIJVNCOPK-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(2,2,4-trimethyl-3h-1,4-benzoxazin-6-yl)pyridine-3-carboxamide Chemical compound C1=C2N(C)CC(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YMRSATIJVNCOPK-UHFFFAOYSA-N 0.000 claims 1
- COIKPNQSXNEPGS-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 COIKPNQSXNEPGS-UHFFFAOYSA-N 0.000 claims 1
- NJTGDBWQCMIQSD-UHFFFAOYSA-N 2-(pyrimidin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2N=CN=CC=2)=C1 NJTGDBWQCMIQSD-UHFFFAOYSA-N 0.000 claims 1
- QKLUVLMTCUXCEY-UHFFFAOYSA-N 2-(quinolin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC1=CC=NC2=CC=CC=C12 QKLUVLMTCUXCEY-UHFFFAOYSA-N 0.000 claims 1
- LTUPGTYYMNFEJH-UHFFFAOYSA-N 2-(quinolin-6-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C3C=CC=NC3=CC=2)=C1 LTUPGTYYMNFEJH-UHFFFAOYSA-N 0.000 claims 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims 1
- HOKUTCLIRMVHQV-UHFFFAOYSA-N 2-[(1-pyridin-2-ylpyrrolidin-3-yl)amino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NC2CN(CC2)C=2N=CC=CC=2)=C1 HOKUTCLIRMVHQV-UHFFFAOYSA-N 0.000 claims 1
- TXTUPLWKPJPKBP-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-(4-propan-2-ylphenyl)pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)C)=C1 TXTUPLWKPJPKBP-UHFFFAOYSA-N 0.000 claims 1
- CERDGDLLQVHYPX-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-(piperazin-1-ylmethyl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CN3CCNCC3)C=2)C(F)(F)F)=C1 CERDGDLLQVHYPX-UHFFFAOYSA-N 0.000 claims 1
- NYLOKYVJQDJMQZ-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-(piperidin-4-ylmethoxy)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CCNCC3)C=2)C(F)(F)F)=C1 NYLOKYVJQDJMQZ-UHFFFAOYSA-N 0.000 claims 1
- TXOGEIFORPBDHE-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[3-[(1-methylpyrrolidin-2-yl)methoxy]-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3N(CCC3)C)C=2)C(F)(F)F)=C1 TXOGEIFORPBDHE-UHFFFAOYSA-N 0.000 claims 1
- ROPVZFCDWKRFKJ-UHFFFAOYSA-N 2-[(2-methoxypyridin-4-yl)methylamino]-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C2CCN(C)CC2)=C1 ROPVZFCDWKRFKJ-UHFFFAOYSA-N 0.000 claims 1
- SSCBBNIHQRXPIR-UHFFFAOYSA-N 2-[2-(pyridin-2-ylamino)ethylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCNC=2N=CC=CC=2)=C1 SSCBBNIHQRXPIR-UHFFFAOYSA-N 0.000 claims 1
- INXYXWVQQJQGIO-UHFFFAOYSA-N 2-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(C(F)(F)F)(C1=CC=C(C=C1)C1=C(C(=O)N)C=CC=N1)F INXYXWVQQJQGIO-UHFFFAOYSA-N 0.000 claims 1
- XYCDDKZBMCXWAK-UHFFFAOYSA-N 2-[[2-(1-benzhydrylazetidin-3-yl)oxypyridin-4-yl]methylamino]-n-(4-tert-butylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 XYCDDKZBMCXWAK-UHFFFAOYSA-N 0.000 claims 1
- AHKVAESKNOYUMX-UHFFFAOYSA-N 2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 AHKVAESKNOYUMX-UHFFFAOYSA-N 0.000 claims 1
- XIQXYURANRUOSO-UHFFFAOYSA-N 2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 XIQXYURANRUOSO-UHFFFAOYSA-N 0.000 claims 1
- IEQVZGWSOKYXIG-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C(OCCN3CCOCC3)N=CC=2)=C1 IEQVZGWSOKYXIG-UHFFFAOYSA-N 0.000 claims 1
- MAKBQHLZGNZKQT-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 MAKBQHLZGNZKQT-UHFFFAOYSA-N 0.000 claims 1
- RCLJTNULOBRPSH-UHFFFAOYSA-N 2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 RCLJTNULOBRPSH-UHFFFAOYSA-N 0.000 claims 1
- PPKHCDXFNAAYJK-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCCN2CCOCC2)=C1 PPKHCDXFNAAYJK-UHFFFAOYSA-N 0.000 claims 1
- PHOULOWXCBGHLV-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2N=C(NCCCN3CCOCC3)N=CC=2)=C1 PHOULOWXCBGHLV-UHFFFAOYSA-N 0.000 claims 1
- QACHNSLVBBEDKH-UHFFFAOYSA-N 2-[[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(NCCCN2CCOCC2)=N1 QACHNSLVBBEDKH-UHFFFAOYSA-N 0.000 claims 1
- HZQVYXSXHOVAOQ-UHFFFAOYSA-N 2-[[2-(azetidin-3-yloxy)pyridin-4-yl]methylamino]-n-(4-tert-butylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OC2CNC2)=C1 HZQVYXSXHOVAOQ-UHFFFAOYSA-N 0.000 claims 1
- QWPCFTMDAOHVNP-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[3-(1-methylpiperidin-4-yl)-5-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(C=2)C2CCN(C)CC2)C(F)(F)F)=CC=N1 QWPCFTMDAOHVNP-UHFFFAOYSA-N 0.000 claims 1
- SBTNGLZXVQGGMX-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 SBTNGLZXVQGGMX-UHFFFAOYSA-N 0.000 claims 1
- MNTZQGOXCKQRJL-UHFFFAOYSA-N 2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 MNTZQGOXCKQRJL-UHFFFAOYSA-N 0.000 claims 1
- BYRCEWFUMAJVCS-UHFFFAOYSA-N 2-[[2-[(1-methylpyrrolidin-2-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound CN1CCCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 BYRCEWFUMAJVCS-UHFFFAOYSA-N 0.000 claims 1
- PBGIJPWVDAQQCY-UHFFFAOYSA-N 2-[[2-[(1-propan-2-ylazetidin-3-yl)methoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1N(C(C)C)CC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 PBGIJPWVDAQQCY-UHFFFAOYSA-N 0.000 claims 1
- SNBHXHNYLUUFIL-UHFFFAOYSA-N 2-[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]pyridin-4-yl]methylamino]-6-fluoro-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1=NC(OCCOCCN(C)C)=CC(CNC=2C(=CC=C(F)N=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 SNBHXHNYLUUFIL-UHFFFAOYSA-N 0.000 claims 1
- LBNUPUAGNWOLIF-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=CC=N1 LBNUPUAGNWOLIF-UHFFFAOYSA-N 0.000 claims 1
- LJIIHWGLUXQUAG-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)C(F)(F)F)=CC=N1 LJIIHWGLUXQUAG-UHFFFAOYSA-N 0.000 claims 1
- RWGCMIAKFYQOLL-UHFFFAOYSA-N 2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]-n-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=CC=N1 RWGCMIAKFYQOLL-UHFFFAOYSA-N 0.000 claims 1
- AGSDASDGMNDAIE-UHFFFAOYSA-N 2-aminopyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(N)=C1 AGSDASDGMNDAIE-UHFFFAOYSA-N 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- GPFCIUJVYMETBL-UHFFFAOYSA-N 5-bromo-n-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC(Br)=CN=C1NCC1=CC=NC=C1 GPFCIUJVYMETBL-UHFFFAOYSA-N 0.000 claims 1
- GKJDPAHTZVRQEZ-UHFFFAOYSA-N 5-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC(F)=CN=C1NCC1=CC=NC=C1 GKJDPAHTZVRQEZ-UHFFFAOYSA-N 0.000 claims 1
- ONNJAGRQSIAWEJ-UHFFFAOYSA-N 6-chloro-5-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC(F)=C(Cl)N=C1NCC1=CC=NC=C1 ONNJAGRQSIAWEJ-UHFFFAOYSA-N 0.000 claims 1
- IXHFATWAZQPRJW-UHFFFAOYSA-N 6-chloro-n-(3-chlorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=NC(Cl)=CC=2)NCC=2C=CN=CC=2)=C1 IXHFATWAZQPRJW-UHFFFAOYSA-N 0.000 claims 1
- DVIUDAIRNHXRFA-UHFFFAOYSA-N 6-fluoro-2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound C=1C=NC=CC=1CNC1=NC(F)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 DVIUDAIRNHXRFA-UHFFFAOYSA-N 0.000 claims 1
- DHVHQZSWWJWAHU-UHFFFAOYSA-N 6-fluoro-n-(4-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=C(F)N=C1NCC1=CC=NC=C1 DHVHQZSWWJWAHU-UHFFFAOYSA-N 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- URBJDFIKIVBIHQ-UHFFFAOYSA-N CCl.N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C(=O)O)C=C1 Chemical compound CCl.N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C(=O)O)C=C1 URBJDFIKIVBIHQ-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- AJHJQHFJVJEBLL-UHFFFAOYSA-N Cl.C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 AJHJQHFJVJEBLL-UHFFFAOYSA-N 0.000 claims 1
- QHHOBCMFMNGWJO-UHFFFAOYSA-N Cl.C=1C=CC2=CC=CN=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1.FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 Chemical compound Cl.C=1C=CC2=CC=CN=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1.FC(F)(F)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 QHHOBCMFMNGWJO-UHFFFAOYSA-N 0.000 claims 1
- FRSHTXKRAWJWLT-UHFFFAOYSA-N Cl.C=1C=CC=2CCCCC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.C=1C=CC=2CCCCC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 FRSHTXKRAWJWLT-UHFFFAOYSA-N 0.000 claims 1
- XJWRDKINUDCQET-UHFFFAOYSA-N Cl.FC1=C(F)C(F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 Chemical compound Cl.FC1=C(F)C(F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 XJWRDKINUDCQET-UHFFFAOYSA-N 0.000 claims 1
- CPJDCDFSDJDXBE-UHFFFAOYSA-N N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)OCCC1NCCCC1 Chemical compound N1=CC=C(C=C1)CNC1=NC=CC=C1C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)OCCC1NCCCC1 CPJDCDFSDJDXBE-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000003939 benzylamines Chemical class 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- SMYFIVSTUSZAQE-UHFFFAOYSA-N n-(1-acetyl-2,3-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CCC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SMYFIVSTUSZAQE-UHFFFAOYSA-N 0.000 claims 1
- JYMFZDXRKLPERK-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2OCCC2=CC(CNC2=NC=CC=C2C(=O)NC2=CC=C3C(C)(C)CN(C3=C2)C(=O)C)=C1 JYMFZDXRKLPERK-UHFFFAOYSA-N 0.000 claims 1
- PCBJMPHFCPGDOA-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=C1 PCBJMPHFCPGDOA-UHFFFAOYSA-N 0.000 claims 1
- YXZVNJFQHDYYMB-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 YXZVNJFQHDYYMB-UHFFFAOYSA-N 0.000 claims 1
- UDPWIPQPPRGTBJ-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1OCCN1CCOCC1 UDPWIPQPPRGTBJ-UHFFFAOYSA-N 0.000 claims 1
- NCBQRLJNOYWQKM-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-(3-morpholin-4-ylpropylamino)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1NCCCN1CCOCC1 NCBQRLJNOYWQKM-UHFFFAOYSA-N 0.000 claims 1
- ZKHWMCVUDATADE-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 ZKHWMCVUDATADE-UHFFFAOYSA-N 0.000 claims 1
- VVCFSPYQWQPPPO-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=CC=N1 VVCFSPYQWQPPPO-UHFFFAOYSA-N 0.000 claims 1
- HPYHOOUXTPVSMT-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(C)=O)(C)C)=CC=2)=N1 HPYHOOUXTPVSMT-UHFFFAOYSA-N 0.000 claims 1
- OTNXTXUZILTZNA-UHFFFAOYSA-N n-(1-bromoisoquinolin-3-yl)-6-fluoro-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound N=1C(F)=CC=C(C(=O)NC=2N=C(Br)C3=CC=CC=C3C=2)C=1NCC1=CC=NC=C1 OTNXTXUZILTZNA-UHFFFAOYSA-N 0.000 claims 1
- VJDQMBCYBAQIMT-UHFFFAOYSA-N n-(1h-indol-5-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VJDQMBCYBAQIMT-UHFFFAOYSA-N 0.000 claims 1
- RIPLKGXLISXLCH-UHFFFAOYSA-N n-(1h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C=CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RIPLKGXLISXLCH-UHFFFAOYSA-N 0.000 claims 1
- IHNKWRULZICRCP-UHFFFAOYSA-N n-(1h-indol-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CC=2C=CNC=2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IHNKWRULZICRCP-UHFFFAOYSA-N 0.000 claims 1
- YWTDZDOTXLSQIL-UHFFFAOYSA-N n-(2,2-dimethyl-3,4-dihydro-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2OC(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YWTDZDOTXLSQIL-UHFFFAOYSA-N 0.000 claims 1
- XIQMSHOOZLOEHV-UHFFFAOYSA-N n-(2,2-dimethyl-3-oxo-4h-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2NC(=O)C(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 XIQMSHOOZLOEHV-UHFFFAOYSA-N 0.000 claims 1
- BUDCPIVSSBWUMO-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2CC1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BUDCPIVSSBWUMO-UHFFFAOYSA-N 0.000 claims 1
- OEZQZEQUTLOKTO-UHFFFAOYSA-N n-(2,3-dihydro-1h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2CCNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OEZQZEQUTLOKTO-UHFFFAOYSA-N 0.000 claims 1
- HCYMVVRCWLJAEZ-UHFFFAOYSA-N n-(2-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC1=CC=CC=C1OC1=CC=CC=C1 HCYMVVRCWLJAEZ-UHFFFAOYSA-N 0.000 claims 1
- KYJBFKIOZUXHFX-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=C1 KYJBFKIOZUXHFX-UHFFFAOYSA-N 0.000 claims 1
- VYBOPFMRQIOZEG-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(1-methylpiperidin-4-yl)oxypyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 VYBOPFMRQIOZEG-UHFFFAOYSA-N 0.000 claims 1
- KYBXRQHAJWDMGN-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC(C=1)=CC=NC=1OCCN1CCOCC1 KYBXRQHAJWDMGN-UHFFFAOYSA-N 0.000 claims 1
- HSKJFFKAHWCESH-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-(2-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C=1C(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=NC=1OCC(C)N1CCOCC1 HSKJFFKAHWCESH-UHFFFAOYSA-N 0.000 claims 1
- RQNIKVDISSISFT-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 RQNIKVDISSISFT-UHFFFAOYSA-N 0.000 claims 1
- BIWVHHRPMXPYFE-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 BIWVHHRPMXPYFE-UHFFFAOYSA-N 0.000 claims 1
- CJOSBJQFCCDYLS-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=N1 CJOSBJQFCCDYLS-UHFFFAOYSA-N 0.000 claims 1
- LKFJIAOIVGBNQD-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3)(C)C)=CC=2)=CC=N1 LKFJIAOIVGBNQD-UHFFFAOYSA-N 0.000 claims 1
- RYUOHJFJSRQTNX-UHFFFAOYSA-N n-(3,3-dimethyl-1-piperidin-4-yl-2h-indol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C12=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)CN1C1CCNCC1 RYUOHJFJSRQTNX-UHFFFAOYSA-N 0.000 claims 1
- OBVVHNKKESTIQE-UHFFFAOYSA-N n-(3,3-dimethyl-1-piperidin-4-yl-2h-indol-6-yl)-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C3CCNCC3)(C)C)=CC=2)=C1 OBVVHNKKESTIQE-UHFFFAOYSA-N 0.000 claims 1
- BXOKJVYFRVHMLH-UHFFFAOYSA-N n-(3,3-dimethyl-2h-1-benzofuran-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)COC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BXOKJVYFRVHMLH-UHFFFAOYSA-N 0.000 claims 1
- FCFABUOVTFFWOG-UHFFFAOYSA-N n-(3,3-dimethyl-2h-1-benzofuran-6-yl)-2-[[2-[(1-methylpiperidin-4-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CO3)(C)C)=CC=2)=CC=N1 FCFABUOVTFFWOG-UHFFFAOYSA-N 0.000 claims 1
- YRFCQBDQLMTWNI-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-6-(2-morpholin-4-ylethylamino)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C(C(=N1)NCC=2C=CN=CC=2)=CC=C1NCCN1CCOCC1 YRFCQBDQLMTWNI-UHFFFAOYSA-N 0.000 claims 1
- JVOUUCKMYRZJFZ-UHFFFAOYSA-N n-(3-benzylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1CC1=CC=CC=C1 JVOUUCKMYRZJFZ-UHFFFAOYSA-N 0.000 claims 1
- ATZPTMHFZCFQEZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(2-pyridin-4-ylethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.ClC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=CN=CC=2)=C1 ATZPTMHFZCFQEZ-UHFFFAOYSA-N 0.000 claims 1
- VPSIZGXQXQGXAD-UHFFFAOYSA-N n-(3-ethylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 VPSIZGXQXQGXAD-UHFFFAOYSA-N 0.000 claims 1
- FTNXOWIWIXTBKQ-UHFFFAOYSA-N n-(3-hydroxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound OC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 FTNXOWIWIXTBKQ-UHFFFAOYSA-N 0.000 claims 1
- CCXZIUPUBKQLLC-UHFFFAOYSA-N n-(3-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1OC1=CC=CC=C1 CCXZIUPUBKQLLC-UHFFFAOYSA-N 0.000 claims 1
- MAVHARHYZLDACC-UHFFFAOYSA-N n-(3-phenylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 MAVHARHYZLDACC-UHFFFAOYSA-N 0.000 claims 1
- CDBAIDSAFYSGIZ-UHFFFAOYSA-N n-(3-propan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 CDBAIDSAFYSGIZ-UHFFFAOYSA-N 0.000 claims 1
- TXGPTKAMEJJTBS-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 TXGPTKAMEJJTBS-UHFFFAOYSA-N 0.000 claims 1
- OLGLAAMYUFFAFR-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-(3-morpholin-4-ylpropoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound O1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCCN2CCOCC2)=C1 OLGLAAMYUFFAFR-UHFFFAOYSA-N 0.000 claims 1
- GCZKZEPEZBTEIV-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 GCZKZEPEZBTEIV-UHFFFAOYSA-N 0.000 claims 1
- ZVUCDXVCCTUQTG-UHFFFAOYSA-N n-(3-tert-butyl-1,2-oxazol-5-yl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2ON=C(C=2)C(C)(C)C)=CC=N1 ZVUCDXVCCTUQTG-UHFFFAOYSA-N 0.000 claims 1
- YCCPQXMCCWWZTM-UHFFFAOYSA-N n-(4,4-dimethyl-1-oxo-2,3-dihydroisoquinolin-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNC(=O)C2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YCCPQXMCCWWZTM-UHFFFAOYSA-N 0.000 claims 1
- CPGMAHUWDQEJAL-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 CPGMAHUWDQEJAL-UHFFFAOYSA-N 0.000 claims 1
- HNOKSHCLWZNCCT-UHFFFAOYSA-N n-(4-acetyl-2,2-dimethyl-3h-1,4-benzoxazin-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)OC2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HNOKSHCLWZNCCT-UHFFFAOYSA-N 0.000 claims 1
- KYOKWCJDBBJSAE-UHFFFAOYSA-N n-(4-benzylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1CC1=CC=CC=C1 KYOKWCJDBBJSAE-UHFFFAOYSA-N 0.000 claims 1
- IJDXKJUJRKHXLD-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC1=CC(Br)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IJDXKJUJRKHXLD-UHFFFAOYSA-N 0.000 claims 1
- FNIPQUCQBWNRKB-UHFFFAOYSA-N n-(4-butan-2-ylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 FNIPQUCQBWNRKB-UHFFFAOYSA-N 0.000 claims 1
- AEYMCJZBQPIIEM-UHFFFAOYSA-N n-(4-butan-2-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 AEYMCJZBQPIIEM-UHFFFAOYSA-N 0.000 claims 1
- NGMFUXHADICHSR-UHFFFAOYSA-N n-(4-butylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCCC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 NGMFUXHADICHSR-UHFFFAOYSA-N 0.000 claims 1
- HEVSAJPOQSSZLF-UHFFFAOYSA-N n-(4-chloro-3-sulfamoylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 HEVSAJPOQSSZLF-UHFFFAOYSA-N 0.000 claims 1
- BTLFSXOBYLGYAL-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 BTLFSXOBYLGYAL-UHFFFAOYSA-N 0.000 claims 1
- LHVHZZPCFAQYLD-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(pyridin-4-ylmethylideneamino)pyridine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=NC=C1N=CC1=CC=NC=C1 LHVHZZPCFAQYLD-UHFFFAOYSA-N 0.000 claims 1
- DKWNJUQHGBDIDC-UHFFFAOYSA-N n-(4-cyanonaphthalen-1-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=C(C#N)C2=CC=CC=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 DKWNJUQHGBDIDC-UHFFFAOYSA-N 0.000 claims 1
- KNNBCOTVZSLLAJ-UHFFFAOYSA-N n-(4-cyclohexylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1CCCCC1 KNNBCOTVZSLLAJ-UHFFFAOYSA-N 0.000 claims 1
- VJSIHVAITVXFNF-UHFFFAOYSA-N n-(4-ethylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VJSIHVAITVXFNF-UHFFFAOYSA-N 0.000 claims 1
- RLCSOSKPEXBPHZ-UHFFFAOYSA-N n-(4-imidazol-1-ylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1N1C=CN=C1 RLCSOSKPEXBPHZ-UHFFFAOYSA-N 0.000 claims 1
- WRQFRRBPQKNLRQ-UHFFFAOYSA-N n-(4-iodophenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(I)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 WRQFRRBPQKNLRQ-UHFFFAOYSA-N 0.000 claims 1
- QPZGDJJQONYBID-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(2-pyridin-2-ylethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCCC=2N=CC=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 QPZGDJJQONYBID-UHFFFAOYSA-N 0.000 claims 1
- NYNCBNDLRMBIKW-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCCC=2C=NC=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 NYNCBNDLRMBIKW-UHFFFAOYSA-N 0.000 claims 1
- XRCHIURCFJPJSO-UHFFFAOYSA-N n-(4-phenoxyphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1OC1=CC=CC=C1 XRCHIURCFJPJSO-UHFFFAOYSA-N 0.000 claims 1
- OIKVIWBBKQKRPV-UHFFFAOYSA-N n-(4-phenylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1=CC=CC=C1 OIKVIWBBKQKRPV-UHFFFAOYSA-N 0.000 claims 1
- KSAXCVWMNKSCFQ-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 KSAXCVWMNKSCFQ-UHFFFAOYSA-N 0.000 claims 1
- NBAJKMDQEUEQMW-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 NBAJKMDQEUEQMW-UHFFFAOYSA-N 0.000 claims 1
- KNXMJHFNMXPJOO-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-2-[2-(1h-1,2,4-triazol-5-yl)ethylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=NNC=N1 KNXMJHFNMXPJOO-UHFFFAOYSA-N 0.000 claims 1
- UXTVVIABVSUZEU-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-4-(pyridin-4-ylmethylamino)pyrimidine-5-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1NC(=O)C1=CN=CN=C1NCC1=CC=NC=C1 UXTVVIABVSUZEU-UHFFFAOYSA-N 0.000 claims 1
- AJUCYOXULSCKSJ-UHFFFAOYSA-N n-(4-propan-2-ylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)C1=CC=NC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 AJUCYOXULSCKSJ-UHFFFAOYSA-N 0.000 claims 1
- INYJVJWHVRXXFY-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 INYJVJWHVRXXFY-UHFFFAOYSA-N 0.000 claims 1
- VPBOSWJGTMJBGG-UHFFFAOYSA-N n-(4-tert-butyl-3-nitrophenyl)-2-(pyridin-2-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=CC=N1 VPBOSWJGTMJBGG-UHFFFAOYSA-N 0.000 claims 1
- DWCNVTQMIOJUDB-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCCC1=CC=CN=C1 DWCNVTQMIOJUDB-UHFFFAOYSA-N 0.000 claims 1
- YAPUZDQPAAAEDA-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YAPUZDQPAAAEDA-UHFFFAOYSA-N 0.000 claims 1
- WJIJHBZARDSRNM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 WJIJHBZARDSRNM-UHFFFAOYSA-N 0.000 claims 1
- YXEALWXWTUTJEV-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(quinolin-6-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=C(N=CC=C2)C2=C1 YXEALWXWTUTJEV-UHFFFAOYSA-N 0.000 claims 1
- FRCKJEGIERNSJM-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[(2-chloropyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(Cl)=C1 FRCKJEGIERNSJM-UHFFFAOYSA-N 0.000 claims 1
- UVKOLUKOGSATHY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[(2-ethylpyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(CC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 UVKOLUKOGSATHY-UHFFFAOYSA-N 0.000 claims 1
- KUJJCXJIGPMUSY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(2-morpholin-4-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCOCC2)=C1 KUJJCXJIGPMUSY-UHFFFAOYSA-N 0.000 claims 1
- HFZBCBWADXBTKQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCCC2)=C1 HFZBCBWADXBTKQ-UHFFFAOYSA-N 0.000 claims 1
- IPGXYZZDIYSOQV-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[(1-propan-2-ylazetidin-3-yl)methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1N(C(C)C)CC1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 IPGXYZZDIYSOQV-UHFFFAOYSA-N 0.000 claims 1
- QNKQVIYUJWTRFC-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpiperidin-4-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 QNKQVIYUJWTRFC-UHFFFAOYSA-N 0.000 claims 1
- UEKVMDATIWSDMF-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 UEKVMDATIWSDMF-UHFFFAOYSA-N 0.000 claims 1
- FQBRBMGUWZLWJQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCCC1CCNC1=NC=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=N1 FQBRBMGUWZLWJQ-UHFFFAOYSA-N 0.000 claims 1
- VFCBJNUUGQRNHY-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[2-[2-(dimethylamino)ethoxy]ethoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OCCOCCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 VFCBJNUUGQRNHY-UHFFFAOYSA-N 0.000 claims 1
- KNDBVDAEJLUQNW-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[3-(1-methylpiperidin-4-yl)propoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CCCOC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 KNDBVDAEJLUQNW-UHFFFAOYSA-N 0.000 claims 1
- CNRDVPVABNSSAW-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-[[2-[3-(dimethylamino)prop-1-ynyl]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=NC(C#CCN(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=C1 CNRDVPVABNSSAW-UHFFFAOYSA-N 0.000 claims 1
- UGSVSPULGCMCKT-HSZRJFAPSA-N n-(4-tert-butylphenyl)-2-[[2-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound CN1CCC[C@@H]1COC1=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=CC(=CC=2)C(C)(C)C)=CC=N1 UGSVSPULGCMCKT-HSZRJFAPSA-N 0.000 claims 1
- HZHWQMINUBOGGQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-6-fluoro-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=C(F)N=C1NCC1=CC=NC=C1 HZHWQMINUBOGGQ-UHFFFAOYSA-N 0.000 claims 1
- QJNSCGAVOHNGNE-UHFFFAOYSA-N n-(4-tert-butylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CC(C)(C)C1=CC=NC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 QJNSCGAVOHNGNE-UHFFFAOYSA-N 0.000 claims 1
- ORUDYBDQLKABCG-UHFFFAOYSA-N n-(5-phenyl-1h-pyrazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(NN=1)=CC=1C1=CC=CC=C1 ORUDYBDQLKABCG-UHFFFAOYSA-N 0.000 claims 1
- UWJPGIUSIAQKQE-UHFFFAOYSA-N n-(5-tert-butyl-1,2-oxazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound O1C(C(C)(C)C)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 UWJPGIUSIAQKQE-UHFFFAOYSA-N 0.000 claims 1
- LWEQAKJMOKEOET-UHFFFAOYSA-N n-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound S1C(C(C)(C)C)=NN=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 LWEQAKJMOKEOET-UHFFFAOYSA-N 0.000 claims 1
- VKWMLHPKHNARJP-UHFFFAOYSA-N n-(5-tert-butyl-1h-pyrazol-3-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound N1N=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 VKWMLHPKHNARJP-UHFFFAOYSA-N 0.000 claims 1
- URUDDEQMXIFTCS-UHFFFAOYSA-N n-(6-ethylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 URUDDEQMXIFTCS-UHFFFAOYSA-N 0.000 claims 1
- BIAMLRWIGLAALI-UHFFFAOYSA-N n-(6-propylpyridin-2-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CCCC1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=N1 BIAMLRWIGLAALI-UHFFFAOYSA-N 0.000 claims 1
- FWVIMMJFCOQNGY-UHFFFAOYSA-N n-[1-(1-methylpiperidin-4-yl)-2,3-dihydroindol-6-yl]-2-(2-pyridin-3-ylethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCCC=3C=NC=CC=3)=CC=C2CC1 FWVIMMJFCOQNGY-UHFFFAOYSA-N 0.000 claims 1
- HXTBDNBGKYWDAP-UHFFFAOYSA-N n-[1-(1-methylpiperidin-4-yl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2CC1 HXTBDNBGKYWDAP-UHFFFAOYSA-N 0.000 claims 1
- WVRSGRIXLWUHOD-UHFFFAOYSA-N n-[1-(2-morpholin-4-ylethyl)indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C12)=CC=C1C=CN2CCN1CCOCC1 WVRSGRIXLWUHOD-UHFFFAOYSA-N 0.000 claims 1
- IBEXLNCTALRTPQ-UHFFFAOYSA-N n-[1-(2-piperidin-2-ylacetyl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CC2=CC=C(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)C=C2N1C(=O)CC1CCCCN1 IBEXLNCTALRTPQ-UHFFFAOYSA-N 0.000 claims 1
- NUOBXRVOEBRLDO-UHFFFAOYSA-N n-[1-(2-piperidin-2-ylethyl)-2,3-dihydroindol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C12)=CC=C1CCN2CCC1CCCCN1 NUOBXRVOEBRLDO-UHFFFAOYSA-N 0.000 claims 1
- KMYYPFXBWZQPDY-UHFFFAOYSA-N n-[1-[2-(dimethylamino)acetyl]-3,3-dimethyl-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)CN(C)C)(C)C)=CC=2)=C1 KMYYPFXBWZQPDY-UHFFFAOYSA-N 0.000 claims 1
- BWGOLYZJXYJGNW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(1-methylpiperidin-4-yl)-2h-indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1N1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 BWGOLYZJXYJGNW-UHFFFAOYSA-N 0.000 claims 1
- RQGSOSPQIFZFSU-UHFFFAOYSA-N n-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3CC3CCNCC3)(C)C)=CC=2)=C1 RQGSOSPQIFZFSU-UHFFFAOYSA-N 0.000 claims 1
- BPZQMIOAOMVLBW-UHFFFAOYSA-N n-[3,3-dimethyl-1-(pyrrolidin-2-ylmethoxy)-2h-indol-6-yl]-2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3OCC3NCCC3)(C)C)=CC=2)=C1 BPZQMIOAOMVLBW-UHFFFAOYSA-N 0.000 claims 1
- XVCCSOVZWSRLQQ-UHFFFAOYSA-N n-[3,3-dimethyl-1-[(1-methylpiperidin-4-yl)methyl]-2h-indol-6-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 XVCCSOVZWSRLQQ-UHFFFAOYSA-N 0.000 claims 1
- GZEPKFYLNUJNBH-UHFFFAOYSA-N n-[3,5-bis(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC(C(F)(F)F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 GZEPKFYLNUJNBH-UHFFFAOYSA-N 0.000 claims 1
- QMKWTBXPMXDUQL-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QMKWTBXPMXDUQL-UHFFFAOYSA-N 0.000 claims 1
- AIZNXAWAECYQQJ-UHFFFAOYSA-N n-[3-(1-methylpiperidin-4-yl)oxy-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 AIZNXAWAECYQQJ-UHFFFAOYSA-N 0.000 claims 1
- SBOPANWRTFAKFW-UHFFFAOYSA-N n-[3-(2-piperidin-1-ylethoxy)-4-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(OCCN2CCCCC2)C(C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SBOPANWRTFAKFW-UHFFFAOYSA-N 0.000 claims 1
- RVLBMLRUNIEDRY-UHFFFAOYSA-N n-[3-(3-morpholin-4-ylpropyl)-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=CC=1CCCN1CCOCC1 RVLBMLRUNIEDRY-UHFFFAOYSA-N 0.000 claims 1
- PJPVFLXGPQUPRO-UHFFFAOYSA-N n-[3-(3-piperidin-1-ylpropyl)-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=CC=1CCCN1CCCCC1 PJPVFLXGPQUPRO-UHFFFAOYSA-N 0.000 claims 1
- HBZADFBPIMGDHL-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 HBZADFBPIMGDHL-UHFFFAOYSA-N 0.000 claims 1
- YFQOPDISULLBEX-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 YFQOPDISULLBEX-UHFFFAOYSA-N 0.000 claims 1
- LUQYQPGSUULSRK-UHFFFAOYSA-N n-[3-[(1-methylpiperidin-4-yl)methoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F LUQYQPGSUULSRK-UHFFFAOYSA-N 0.000 claims 1
- ZEGOYJVJXXDBHE-UHFFFAOYSA-N n-[3-[(1-methylpiperidin-4-yl)methyl]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 ZEGOYJVJXXDBHE-UHFFFAOYSA-N 0.000 claims 1
- QCYXPNPXDUIHFC-HXUWFJFHSA-N n-[3-[(2r)-2-hydroxy-3-pyrrolidin-1-ylpropoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C([C@H](O)CN1CCCC1)OC(C(=CC=1)C(F)(F)C(F)(F)F)=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QCYXPNPXDUIHFC-HXUWFJFHSA-N 0.000 claims 1
- QCYXPNPXDUIHFC-FQEVSTJZSA-N n-[3-[(2s)-2-hydroxy-3-pyrrolidin-1-ylpropoxy]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C([C@@H](O)CN1CCCC1)OC(C(=CC=1)C(F)(F)C(F)(F)F)=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QCYXPNPXDUIHFC-FQEVSTJZSA-N 0.000 claims 1
- NVIFFUXBUQMLMT-UHFFFAOYSA-N n-[3-[(4-methylpiperazin-1-yl)methyl]-4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NVIFFUXBUQMLMT-UHFFFAOYSA-N 0.000 claims 1
- XZZZSAFQBWVXJP-UHFFFAOYSA-N n-[3-[3-(dimethylamino)propyl]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC(CCCN(C)C)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 XZZZSAFQBWVXJP-UHFFFAOYSA-N 0.000 claims 1
- QNDWXHLAZMTTFF-HXUWFJFHSA-N n-[3-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CN1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 QNDWXHLAZMTTFF-HXUWFJFHSA-N 0.000 claims 1
- YIDKXOVFDQEFSL-UHFFFAOYSA-N n-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 YIDKXOVFDQEFSL-UHFFFAOYSA-N 0.000 claims 1
- HCVSNRUVUNXQAT-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)-3-(2-piperidin-1-ylethoxy)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(OCCN2CCCCC2)C(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HCVSNRUVUNXQAT-UHFFFAOYSA-N 0.000 claims 1
- HHISJRVODGCDMG-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 HHISJRVODGCDMG-UHFFFAOYSA-N 0.000 claims 1
- UWMNUWGCYARTQI-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-(pyrimidin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=N1 UWMNUWGCYARTQI-UHFFFAOYSA-N 0.000 claims 1
- MJLGKPIINGGZCM-UHFFFAOYSA-N n-[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-2-[[2-(2-pyrrolidin-1-ylethoxy)pyridin-4-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC(OCCN2CCCC2)=C1 MJLGKPIINGGZCM-UHFFFAOYSA-N 0.000 claims 1
- GZBOQOFJJBPEDE-UHFFFAOYSA-N n-[4-(1,1,2,2,3,3,4,4,4-nonafluorobutyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 GZBOQOFJJBPEDE-UHFFFAOYSA-N 0.000 claims 1
- BGAVPSNOTCFPDW-UHFFFAOYSA-N n-[4-(2-aminoethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCN)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 BGAVPSNOTCFPDW-UHFFFAOYSA-N 0.000 claims 1
- WAIWQTLSROUTRH-UHFFFAOYSA-N n-[4-(2-methyl-4-morpholin-4-ylbutan-2-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=C(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)C=CC=1C(C)(C)CCN1CCOCC1 WAIWQTLSROUTRH-UHFFFAOYSA-N 0.000 claims 1
- PPPHMJMGRRTAAT-UHFFFAOYSA-N n-[4-(4-chlorophenoxy)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1OC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PPPHMJMGRRTAAT-UHFFFAOYSA-N 0.000 claims 1
- KFHYBLFWLWUHCQ-UHFFFAOYSA-N n-[4-(4-hydroxybutyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=CC(CCCCO)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KFHYBLFWLWUHCQ-UHFFFAOYSA-N 0.000 claims 1
- FJDDTXZRAVOMLY-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)phenyl]-n-[2-(pyridin-4-ylmethylamino)pyridin-3-yl]formamide Chemical compound C1CN(C)CCN1C1=CC=C(N(C=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)C=C1 FJDDTXZRAVOMLY-UHFFFAOYSA-N 0.000 claims 1
- ILFSTPMMQSOOJD-UHFFFAOYSA-N n-[4-(morpholin-4-ylmethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1CN1CCOCC1 ILFSTPMMQSOOJD-UHFFFAOYSA-N 0.000 claims 1
- UQNZRWDAWGMJBS-UHFFFAOYSA-N n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 UQNZRWDAWGMJBS-UHFFFAOYSA-N 0.000 claims 1
- WVRRCUQDZMAVII-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=C1 WVRRCUQDZMAVII-UHFFFAOYSA-N 0.000 claims 1
- KCMIRJFWDFYISD-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-morpholin-4-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCN2CCOCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KCMIRJFWDFYISD-UHFFFAOYSA-N 0.000 claims 1
- KKGIDEBPBZIJRB-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-piperidin-3-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCC2CNCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 KKGIDEBPBZIJRB-UHFFFAOYSA-N 0.000 claims 1
- OMJQWGGFSXFZOU-UHFFFAOYSA-N n-[4-tert-butyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(CCCN2CCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 OMJQWGGFSXFZOU-UHFFFAOYSA-N 0.000 claims 1
- KRFYQNQCQUXSBR-UHFFFAOYSA-N n-[4-tert-butyl-3-(4-methylpiperazin-1-yl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C KRFYQNQCQUXSBR-UHFFFAOYSA-N 0.000 claims 1
- WFFPIRJZLXANMB-UHFFFAOYSA-N n-[4-tert-butyl-3-[(1-methylazetidin-3-yl)methoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1N(C)CC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C WFFPIRJZLXANMB-UHFFFAOYSA-N 0.000 claims 1
- TURDJROVMKFFKH-UHFFFAOYSA-N n-[4-tert-butyl-3-[(1-methylpiperidin-4-yl)methoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1CN(C)CCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C TURDJROVMKFFKH-UHFFFAOYSA-N 0.000 claims 1
- PVAQZNCCTFFIGR-RUDMXATFSA-N n-[4-tert-butyl-3-[(e)-4-pyrrolidin-1-ylbut-1-enyl]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C1=C(\C=C\CCN2CCCC2)C(C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PVAQZNCCTFFIGR-RUDMXATFSA-N 0.000 claims 1
- PHJRTHKWNXYXQC-UHFFFAOYSA-N n-[5-tert-butyl-2-[2-(dimethylamino)ethoxy]phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound CN(C)CCOC1=CC=C(C(C)(C)C)C=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 PHJRTHKWNXYXQC-UHFFFAOYSA-N 0.000 claims 1
- MCUIEWFNWZMXBM-UHFFFAOYSA-N n-isoquinolin-3-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C2=CC=CC=C2C=NC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 MCUIEWFNWZMXBM-UHFFFAOYSA-N 0.000 claims 1
- GTIPBHSTZQVIRN-UHFFFAOYSA-N n-naphthalen-1-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 GTIPBHSTZQVIRN-UHFFFAOYSA-N 0.000 claims 1
- IIQYLJRHXQVBCP-UHFFFAOYSA-N n-naphthalen-2-yl-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C=1C=C2C=CC=CC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 IIQYLJRHXQVBCP-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- NIKQRARLBRMZAI-OAQYLSRUSA-N tert-butyl (2r)-2-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NIKQRARLBRMZAI-OAQYLSRUSA-N 0.000 claims 1
- RRFQDYDKMPHLGV-JOCHJYFZSA-N tert-butyl (2r)-2-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 RRFQDYDKMPHLGV-JOCHJYFZSA-N 0.000 claims 1
- FEYSNEFIARBXHD-OAQYLSRUSA-N tert-butyl (2r)-2-[[5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2-(trifluoromethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)F FEYSNEFIARBXHD-OAQYLSRUSA-N 0.000 claims 1
- NIKQRARLBRMZAI-NRFANRHFSA-N tert-butyl (2s)-2-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F NIKQRARLBRMZAI-NRFANRHFSA-N 0.000 claims 1
- CSQZJFXVJCLZRI-UHFFFAOYSA-N tert-butyl 2-[[2-tert-butyl-4-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1COC(C(=C1)C(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 CSQZJFXVJCLZRI-UHFFFAOYSA-N 0.000 claims 1
- ZMLWTDZGAAIZRM-UHFFFAOYSA-N tert-butyl 2-[[5-[[2-(2,3-dihydro-1-benzofuran-6-ylmethylamino)pyridine-3-carbonyl]amino]-2-(1,1,2,2,2-pentafluoroethyl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=C3OCCC3=CC=2)=CC=C1C(F)(F)C(F)(F)F ZMLWTDZGAAIZRM-UHFFFAOYSA-N 0.000 claims 1
- QTIBLBJWTGESGG-UHFFFAOYSA-N tert-butyl 2-[[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]oxymethyl]pyrrolidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3OCC3N(CCC3)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 QTIBLBJWTGESGG-UHFFFAOYSA-N 0.000 claims 1
- QOOAVFIGIITHMF-UHFFFAOYSA-N tert-butyl 2-amino-3-[3,3-dimethyl-6-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2h-indol-1-yl]-3-oxopropanoate Chemical compound C1=C2N(C(=O)C(N)C(=O)OC(C)(C)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 QOOAVFIGIITHMF-UHFFFAOYSA-N 0.000 claims 1
- MWQSWYRACGHCEW-UHFFFAOYSA-N tert-butyl 2-amino-3-[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]-3-oxopropanoate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)C(N)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 MWQSWYRACGHCEW-UHFFFAOYSA-N 0.000 claims 1
- ZCTOUYXFKCXODN-UHFFFAOYSA-N tert-butyl 3-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1COC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 ZCTOUYXFKCXODN-UHFFFAOYSA-N 0.000 claims 1
- BBGMAEURHQLMTH-UHFFFAOYSA-N tert-butyl 3-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]azetidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CN(C3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 BBGMAEURHQLMTH-UHFFFAOYSA-N 0.000 claims 1
- VWOHUDYCECXLCP-UHFFFAOYSA-N tert-butyl 4-[2-[2-tert-butyl-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(C)(C)C VWOHUDYCECXLCP-UHFFFAOYSA-N 0.000 claims 1
- VTGVDQWJMAIIQY-UHFFFAOYSA-N tert-butyl 4-[3-[[2-(2-pyridin-4-ylethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC(NC(=O)C=2C(=NC=CC=2)NCCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 VTGVDQWJMAIIQY-UHFFFAOYSA-N 0.000 claims 1
- BMGWASDKBNKGEI-UHFFFAOYSA-N tert-butyl 4-[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 BMGWASDKBNKGEI-UHFFFAOYSA-N 0.000 claims 1
- ARTHAKPKOZXFDW-UHFFFAOYSA-N tert-butyl 4-[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 ARTHAKPKOZXFDW-UHFFFAOYSA-N 0.000 claims 1
- PQLNOAQQIXKLPQ-UHFFFAOYSA-N tert-butyl 4-[[2-(1,1,2,2,2-pentafluoroethyl)-5-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC=C1C(F)(F)C(F)(F)F PQLNOAQQIXKLPQ-UHFFFAOYSA-N 0.000 claims 1
- RCABXLXBGYKLTI-UHFFFAOYSA-N tert-butyl 4-[[3,3-dimethyl-6-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=CN=CC=3)=CC=C2C(C)(C)C1 RCABXLXBGYKLTI-UHFFFAOYSA-N 0.000 claims 1
- IJDAUEQFCBFCJH-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC(NC(=O)C=2C(=NC=CC=2)NCC=2C=CN=CC=2)=CC(C(F)(F)F)=C1 IJDAUEQFCBFCJH-UHFFFAOYSA-N 0.000 claims 1
- XPZARCJXYPVIBV-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenoxy]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(OCC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 XPZARCJXYPVIBV-UHFFFAOYSA-N 0.000 claims 1
- XVOGDGCWXZWQJV-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CN3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 XVOGDGCWXZWQJV-UHFFFAOYSA-N 0.000 claims 1
- SYWDCMDDPUTUHL-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-5-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C(C=C(CC3CCN(CC3)C(=O)OC(C)(C)C)C=2)C(F)(F)F)=C1 SYWDCMDDPUTUHL-UHFFFAOYSA-N 0.000 claims 1
- NOXPICRGCBJOJI-UHFFFAOYSA-N tert-butyl 4-[[6-[[2-(2,3-dihydro-1-benzofuran-5-ylmethylamino)pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1C2=CC(NC(=O)C=3C(=NC=CC=3)NCC=3C=C4CCOC4=CC=3)=CC=C2C(C)(C)C1 NOXPICRGCBJOJI-UHFFFAOYSA-N 0.000 claims 1
- ASGMDOZDZHAXQM-UHFFFAOYSA-N tert-butyl 4-[[6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indol-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3CC3CCN(CC3)C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 ASGMDOZDZHAXQM-UHFFFAOYSA-N 0.000 claims 1
- DKRURERGEKGKFC-UHFFFAOYSA-N tert-butyl 6-[[2-[(2-methoxypyridin-4-yl)methylamino]pyridine-3-carbonyl]amino]-3,3-dimethyl-2h-indole-1-carboxylate Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CN=2)C(=O)NC=2C=C3C(C(CN3C(=O)OC(C)(C)C)(C)C)=CC=2)=C1 DKRURERGEKGKFC-UHFFFAOYSA-N 0.000 claims 1
- SWSBOEBCLSTVII-UHFFFAOYSA-N tert-butyl n-[2-[4-[[2-(pyridin-4-ylmethylamino)pyridine-3-carbonyl]amino]phenyl]ethyl]carbamate Chemical compound C1=CC(CCNC(=O)OC(C)(C)C)=CC=C1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 SWSBOEBCLSTVII-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26133901P | 2001-01-12 | 2001-01-12 | |
| US32376401P | 2001-09-19 | 2001-09-19 | |
| US10/046,681 US6995162B2 (en) | 2001-01-12 | 2002-01-10 | Substituted alkylamine derivatives and methods of use |
| PCT/US2002/000743 WO2002066470A1 (en) | 2001-01-12 | 2002-01-11 | Substituted alkylamine derivatives and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097317A Division JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531484A JP2004531484A (ja) | 2004-10-14 |
| JP2004531484A5 true JP2004531484A5 (enExample) | 2005-12-22 |
| JP4408627B2 JP4408627B2 (ja) | 2010-02-03 |
Family
ID=27366957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565984A Expired - Fee Related JP4408627B2 (ja) | 2001-01-12 | 2002-01-11 | 置換アルキルアミン誘導体およびそれの使用方法 |
| JP2009097317A Pending JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009097317A Pending JP2009286777A (ja) | 2001-01-12 | 2009-04-13 | 置換アルキルアミン誘導体およびそれの使用方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6995162B2 (enExample) |
| EP (4) | EP2311808A1 (enExample) |
| JP (2) | JP4408627B2 (enExample) |
| KR (1) | KR100848429B1 (enExample) |
| CN (1) | CN1313464C (enExample) |
| AT (1) | ATE361288T1 (enExample) |
| AU (2) | AU2002248340C8 (enExample) |
| BG (1) | BG66160B1 (enExample) |
| BR (1) | BR0206435A (enExample) |
| CA (1) | CA2434277C (enExample) |
| CY (1) | CY1106748T1 (enExample) |
| CZ (1) | CZ303356B6 (enExample) |
| DE (1) | DE60219887T2 (enExample) |
| DK (1) | DK1358184T3 (enExample) |
| EA (1) | EA006973B1 (enExample) |
| EE (1) | EE05290B1 (enExample) |
| ES (1) | ES2284849T3 (enExample) |
| GE (1) | GEP20053692B (enExample) |
| HU (1) | HUP0302598A2 (enExample) |
| IL (4) | IL156751A0 (enExample) |
| IS (1) | IS2623B (enExample) |
| MX (1) | MXPA03006179A (enExample) |
| NO (1) | NO329306B1 (enExample) |
| NZ (1) | NZ526868A (enExample) |
| PL (1) | PL368209A1 (enExample) |
| PT (1) | PT1358184E (enExample) |
| RS (1) | RS51477B (enExample) |
| SI (1) | SI1358184T1 (enExample) |
| SK (1) | SK287860B6 (enExample) |
| UA (1) | UA77167C2 (enExample) |
| WO (1) | WO2002066470A1 (enExample) |
Families Citing this family (313)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| JP4777648B2 (ja) * | 2002-07-31 | 2011-09-21 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Vegfr−2及びvegfr−3阻害性アントラニルアミドピリジン |
| DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| GB0224316D0 (en) | 2002-10-18 | 2002-11-27 | Syngenta Participations Ag | Chemical compounds |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| PL1602647T3 (pl) | 2003-03-07 | 2014-05-30 | Santen Pharmaceutical Co Ltd | Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| US7978887B2 (en) | 2003-06-17 | 2011-07-12 | Brown University | Methods and apparatus for identifying subject matter in view data |
| EP1639099B1 (en) | 2003-06-27 | 2011-05-18 | Université Laval | Method of isolating cells from umbilical cord |
| EP1648998B1 (en) | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| BRPI0412257A (pt) * | 2003-07-23 | 2006-10-03 | Synta Pharmaceuticals Corp | compostos para inflamação e usos imuno-relacionados |
| ES2222832B1 (es) | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| MXPA06003163A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| AU2004273619A1 (en) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Combinations of a VEGF receptor inhibitor with other therapeutic agents |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| WO2005085201A1 (ja) | 2004-02-17 | 2005-09-15 | Santen Pharmaceutical Co., Ltd. | 置換又は無置換アミノ基を導入した4-ピリジルアルキルチオ基を有する新規環式化合物 |
| CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| US20080167309A1 (en) * | 2004-07-22 | 2008-07-10 | Astex Therapeutics, Ltd. | Pharmaceutical Compounds |
| WO2006034015A1 (en) * | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| ATE474839T1 (de) * | 2005-01-14 | 2010-08-15 | Hoffmann La Roche | Thiazol-4-carboxamid-derivate als mglur5- antagonisten |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| CA2594477C (en) * | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| AU2006221037A1 (en) * | 2005-03-04 | 2006-09-14 | Bayer Pharmaceuticals Corporation | 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| ES2548729T3 (es) * | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio |
| JP4834441B2 (ja) * | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | ピリミジニルアルキルチオ基を有する新規環式化合物 |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| EP1787981A1 (en) * | 2005-11-22 | 2007-05-23 | Bayer CropScience S.A. | New N-phenethylcarboxamide derivatives |
| WO2007062459A1 (en) * | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JP2009526050A (ja) * | 2006-02-10 | 2009-07-16 | アムジエン・インコーポレーテツド | Amg706の水和物形態 |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| EP2032536B1 (en) | 2006-05-30 | 2015-05-06 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| EP2030971B1 (en) | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof |
| AU2007265238A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine H3 receptor |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| AU2007314341B2 (en) * | 2006-10-31 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| KR20150090281A (ko) * | 2006-12-29 | 2015-08-05 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도 |
| ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| PT2188313T (pt) | 2007-08-21 | 2017-12-12 | Amgen Inc | Proteínas de ligação ao antigénio c-fms humano |
| NZ584474A (en) | 2007-10-11 | 2012-06-29 | Vertex Pharma | Amides useful as inhibitors of voltage-gated sodium channels |
| KR20100075631A (ko) | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| US8586571B2 (en) | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN101868454A (zh) | 2007-11-20 | 2010-10-20 | 詹森药业有限公司 | 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 |
| CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| JP5553415B2 (ja) | 2008-08-27 | 2014-07-16 | レオ ファーマ アクティーゼルスカブ | Vegfr−2受容体としてのピリジン誘導体、及びタンパク質チロシンキナーゼ阻害剤 |
| BRPI0920870A2 (pt) | 2008-10-10 | 2018-06-26 | Actelion Pharmaceuticals Ltd | antibióticos de oxazolidinila. |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| TWI600642B (zh) * | 2008-12-05 | 2017-10-01 | 艾伯維有限公司 | 用於治療癌症及免疫疾病之bcl-2-選擇性細胞凋亡誘發劑 |
| WO2010071828A2 (en) | 2008-12-19 | 2010-06-24 | Amgen Inc. | Improved method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| MX2011010694A (es) | 2009-04-16 | 2011-10-21 | Takeda Pharmaceutical | Derivados de n-acil-n'-fenilpiperazina utiles (inter alia) para la profilaxis o tratamiento de diabetes. |
| AR076705A1 (es) | 2009-05-26 | 2011-06-29 | Abbott Lab | Agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2010289802C1 (en) | 2009-08-24 | 2015-04-16 | Neuralstem, Inc. | Synthesis of a neurostimulative piperazine |
| EA201200820A1 (ru) * | 2009-12-08 | 2013-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
| JP2013537918A (ja) | 2010-09-27 | 2013-10-07 | エクセリクシス, インク. | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのmetおよびvegfの二元阻害薬 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| MX349533B (es) | 2010-10-29 | 2017-08-02 | Abbvie Inc | Dispersiones solidas que contienen un agente inductor de apoptosis. |
| BR112013009531A2 (pt) | 2010-11-11 | 2016-07-19 | Redx Pharma Ltd | derivados de fármaco |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| MY191300A (en) | 2010-11-23 | 2022-06-14 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
| US20130266590A1 (en) | 2010-12-13 | 2013-10-10 | Novartis Ag | Dimeric iap inhibitors |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| WO2012112969A1 (en) | 2011-02-18 | 2012-08-23 | Endo Pharmaceuticals Inc. | Aminoindane compounds and use thereof in treating pain |
| JP2014523398A (ja) | 2011-03-23 | 2014-09-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 |
| ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
| WO2012162291A1 (en) * | 2011-05-24 | 2012-11-29 | The Wistar Institute | Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1 |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| KR101412794B1 (ko) * | 2011-07-27 | 2014-07-01 | 보령제약 주식회사 | 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2013025939A2 (en) | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| TWI547493B (zh) | 2011-09-27 | 2016-09-01 | 諾華公司 | 作為突變idh之抑制劑之3-嘧啶-4-基-唑啶-2-酮 |
| JP2015500277A (ja) | 2011-12-05 | 2015-01-05 | ノバルティス アーゲー | アンドロゲン受容体拮抗薬としての環状尿素誘導体 |
| WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| TWI603957B (zh) | 2012-08-15 | 2017-11-01 | 阿沙納生物科學有限責任公司 | 胺基氫茚化合物用於治療膀胱過動症及間質性膀胱炎之用途 |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| ES2644758T3 (es) | 2012-10-16 | 2017-11-30 | Tolero Pharmaceuticals, Inc. | Moduladores de PKM2 y métodos para su uso |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| EP3360870A1 (en) | 2013-02-19 | 2018-08-15 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
| WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015127284A2 (en) | 2014-02-21 | 2015-08-27 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| AU2015314756A1 (en) | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CA2972592A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| CN107592861B (zh) | 2015-03-06 | 2021-06-08 | 法玛克亚公司 | 氟化赖氨酰氧化酶样2抑制剂及其用途 |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107667092B (zh) | 2015-03-25 | 2021-05-28 | 诺华股份有限公司 | 作为fgfr4抑制剂的甲酰化n-杂环衍生物 |
| WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| HUE057837T2 (hu) | 2015-11-03 | 2022-06-28 | Janssen Biotech Inc | PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik |
| EP4424322A3 (en) | 2015-12-17 | 2025-04-16 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| JP6969800B2 (ja) | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体 |
| CA3023216A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN106565599A (zh) * | 2016-06-20 | 2017-04-19 | 中国药科大学 | 2‑氨甲基吡啶基烟酰胺类化合物及其制备方法和应用 |
| KR102565885B1 (ko) | 2016-07-20 | 2023-08-09 | 유니버시티 오브 유타 리서치 파운데이션 | Cd229 car t 세포 및 이의 사용 방법 |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
| CA3036062A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
| HRP20211642T1 (hr) | 2016-12-22 | 2022-01-21 | Amgen Inc. | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, kinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao inhibitori kras g12c za liječenje raka pluća, gušterače ili kolorektalnog karcinoma |
| WO2018129403A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics | Methods for the treatment of neurological disorders |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
| WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| JP7447002B2 (ja) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤 |
| FI3688032T3 (fi) | 2017-09-26 | 2025-12-09 | Cero Therapeutics Holdings Inc | Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019157020A1 (en) | 2018-02-06 | 2019-08-15 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
| CA3094527A1 (en) * | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN112218886A (zh) | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途 |
| KR20210024443A (ko) | 2018-03-28 | 2021-03-05 | 세로 테라퓨틱스, 인코포레이티드 | 세포 면역요법 조성물 및 이의 용도 |
| MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
| JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7361720B2 (ja) | 2018-05-10 | 2023-10-16 | アムジエン・インコーポレーテツド | がんの治療のためのkras g12c阻害剤 |
| US11746157B2 (en) | 2018-05-24 | 2023-09-05 | Janssen Biotech, Inc. | PSMA binding agents and uses thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
| AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Bcmaキメラ抗原受容体及びその使用 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| EP4545101B1 (en) | 2018-07-25 | 2025-12-10 | Advanced Accelerator Applications S.A. | Stable, concentrated radionuclide complex solutions |
| EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME |
| TWI827677B (zh) | 2018-09-18 | 2024-01-01 | 美商尼坎醫療公司 | 作為src同源-2磷酸酶抑制劑之稠合三環衍生物 |
| CA3113241A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| US20210346527A1 (en) | 2018-09-25 | 2021-11-11 | Advanced Accelerator Applications (Italy) Srl | Combination Therapy |
| WO2020068873A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| AU2019384118B2 (en) | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| ES2997190T3 (en) | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| AU2019403486B2 (en) | 2018-12-20 | 2025-04-24 | Amgen Inc. | KIF18A inhibitors |
| WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| CA3130080A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| JP7547360B2 (ja) | 2019-03-22 | 2024-09-09 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法 |
| WO2020212947A1 (en) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| CA3145305A1 (en) | 2019-07-11 | 2021-01-14 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| US20220289724A1 (en) | 2019-08-02 | 2022-09-15 | Amgen Inc. | Kif18a inhibitors |
| CN114391012B (zh) | 2019-08-02 | 2025-10-31 | 美国安进公司 | 作为kif18a抑制剂的吡啶衍生物 |
| CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
| US12435046B2 (en) | 2019-08-15 | 2025-10-07 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| US20240058446A1 (en) | 2019-10-03 | 2024-02-22 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| KR20250175006A (ko) | 2019-11-04 | 2025-12-15 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| EP4058432A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN115397806A (zh) * | 2019-11-25 | 2022-11-25 | 增益治疗股份有限公司 | 芳基和杂芳基化合物及其在与半乳糖脑苷脂酶的活性改变相关的病状中的治疗用途 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| IL293834A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
| WO2021161230A1 (en) * | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
| AU2021409561A1 (en) | 2020-12-22 | 2023-07-06 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス, インコーポレイテッド | イソインドリノン化合物 |
| JP2024504758A (ja) | 2021-01-28 | 2024-02-01 | ヤンセン バイオテツク,インコーポレーテツド | Psma結合タンパク質及びその使用 |
| WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
| BR112023017213A2 (pt) | 2021-02-26 | 2023-11-21 | Kelonia Therapeutics Inc | Vetores lentivirais direcionados a linfócitos |
| WO2022197740A1 (en) * | 2021-03-15 | 2022-09-22 | Board Of Regents, The University Of Texas System | Biaryl amide and heteroaryl amides for treatment of candida albicans infection |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4370522A1 (en) | 2021-07-14 | 2024-05-22 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| KR20240119868A (ko) | 2021-07-28 | 2024-08-06 | 세로 테라퓨틱스, 인코포레이티드 | 키메라 tim4 수용체 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4490146A1 (en) | 2022-03-07 | 2025-01-15 | Amgen Inc. | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| KR20240167846A (ko) | 2022-03-28 | 2024-11-28 | 니캉 테라퓨틱스 인코포레이티드 | 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체 |
| EP4536363A1 (en) | 2022-06-08 | 2025-04-16 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| CN120359029A (zh) | 2022-10-14 | 2025-07-22 | 黑钻治疗公司 | 使用异喹啉或6-氮杂-喹啉衍生物治疗癌症的方法 |
| WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025072462A1 (en) | 2023-09-27 | 2025-04-03 | Nikang Therapeutics, Inc. | Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ras抑制劑 |
| WO2025117616A1 (en) | 2023-11-27 | 2025-06-05 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025117981A1 (en) | 2023-12-02 | 2025-06-05 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025212828A1 (en) | 2024-04-03 | 2025-10-09 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025240536A1 (en) | 2024-05-15 | 2025-11-20 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR216E (fr) * | 1901-03-19 | 1902-11-21 | Compin | Système d'appareil incinérateur pour . manchons à incan-descence |
| CH438343A (de) * | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
| US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
| US3291797A (en) | 1965-10-23 | 1966-12-13 | American Home Prod | 3, 4-dihydro-2h-pyran-2-ylmethyl pteridine derivatives |
| US3822277A (en) * | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
| BE794226A (fr) | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| DE3305755A1 (de) * | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
| DE3642315A1 (de) | 1986-12-11 | 1988-06-23 | Boehringer Mannheim Gmbh | Neue pyrrolobenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
| ES2058656T3 (es) | 1989-04-20 | 1994-11-01 | Boehringer Ingelheim Pharma | 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida. |
| DK0410148T3 (da) | 1989-06-28 | 1994-08-08 | Boehringer Ingelheim Pharma | Hidtil ukendte 5,11-dihydro-6H-dipyrido(3,2-b:2,3-e)-(1,4)diazepin-6-oner og -thioner og deres anvendelse til forebyggelse eller behandling af AIDS |
| CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
| US5571912A (en) * | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
| EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5532358A (en) | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
| US5696127A (en) | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| US5674876A (en) * | 1995-01-20 | 1997-10-07 | Research Development Foundation | ρ-heteroatom-substituted phenols and uses thereof |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| US5770613A (en) * | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5663357A (en) * | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| RU2196137C2 (ru) | 1996-08-08 | 2003-01-10 | Зенека Лимитед | Производные хиназолина и их применение в качестве ингибиторов фактора роста эндотелия сосудов |
| US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| DE19648793A1 (de) * | 1996-11-26 | 1998-05-28 | Basf Ag | Neue Benzamide und deren Anwendung |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| TR199902432T2 (xx) | 1997-04-04 | 2000-01-21 | Prizer Products Inc. | Nikotinamid t�revleri. |
| US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| US6313151B1 (en) * | 1997-06-26 | 2001-11-06 | Eli Lilly And Company | Antithrombotic agents |
| JP2002512633A (ja) * | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
| US6417200B1 (en) * | 1997-06-26 | 2002-07-09 | Eli Lilly And Company | Antithrombotic agents |
| ATE297203T1 (de) * | 1997-06-26 | 2005-06-15 | Lilly Co Eli | Antithrombotische mitteln |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| EP1040108B1 (en) | 1997-12-19 | 2004-02-25 | Schering Aktiengesellschaft | Ortho-anthranilamide derivatives as anti-coagulants |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| TR200003004T2 (tr) * | 1998-04-20 | 2001-02-21 | Basf Aktiengesellschaft | Kalpain önleyicileri olarak heterosiklik ikame edilmiş amidler |
| CA2332957A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| AU761983B2 (en) | 1998-07-08 | 2003-06-12 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation,their use and pharmaceutical preparations comprising them |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| AU1023300A (en) * | 1998-11-06 | 2000-05-29 | London Health Sciences Centre | A multi-channel data acquisition system for the real-time spatial, temporal monitoring and classification of high frequency bandwidth neuronal activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| CA2358091A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Antithrombotic amides |
| US6689780B1 (en) * | 1998-12-23 | 2004-02-10 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor Xa |
| DE69907963T2 (de) | 1998-12-23 | 2004-05-19 | Eli Lilly And Co., Indianapolis | Heteroaromatische amide als inhibitoren von faktor xa |
| JP2002533454A (ja) * | 1998-12-23 | 2002-10-08 | イーライ・リリー・アンド・カンパニー | 芳香族アミド類 |
| KR100838617B1 (ko) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
| JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| MY123528A (en) | 1999-09-16 | 2006-05-31 | Mitsubihsi Tanabe Pharma Corp | Aromatic nitrogen-containing 6-membered cyclic compounds. |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| WO2001055115A1 (en) | 2000-01-27 | 2001-08-02 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| DE10005875B4 (de) * | 2000-02-10 | 2004-05-13 | Koenig & Bauer Ag | Farbzufuhreinrichtung |
| US6509755B2 (en) | 2000-02-29 | 2003-01-21 | Schlumberger Technology Corporation | Method and device for active impedance matching |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| EP1394154A4 (en) * | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE |
| US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| CA2453223A1 (en) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors |
| DK1387838T3 (da) | 2001-05-08 | 2006-08-14 | Schering Ag | Cyanoanthranylamid-derivater og deres anvendelse som lægemidler |
| JP2004528378A (ja) * | 2001-05-08 | 2004-09-16 | シエーリング アクチエンゲゼルシャフト | N−オキシドアントラニルアミド誘導体と医薬製剤としての利用 |
| ATE378049T1 (de) | 2002-02-11 | 2007-11-15 | Pfizer | Nicotinamid-derivate als pde4-hemmer |
| GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US7517894B2 (en) * | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-01-10 US US10/046,681 patent/US6995162B2/en not_active Expired - Lifetime
- 2002-01-11 AU AU2002248340A patent/AU2002248340C8/en not_active Ceased
- 2002-01-11 EP EP10176822A patent/EP2311808A1/en not_active Withdrawn
- 2002-01-11 WO PCT/US2002/000743 patent/WO2002066470A1/en not_active Ceased
- 2002-01-11 EP EP02717325A patent/EP1358184B1/en not_active Expired - Lifetime
- 2002-01-11 KR KR1020037009274A patent/KR100848429B1/ko not_active Expired - Fee Related
- 2002-01-11 JP JP2002565984A patent/JP4408627B2/ja not_active Expired - Fee Related
- 2002-01-11 PT PT02717325T patent/PT1358184E/pt unknown
- 2002-01-11 EP EP10176821A patent/EP2311829A1/en not_active Withdrawn
- 2002-01-11 EE EEP200300324A patent/EE05290B1/xx not_active IP Right Cessation
- 2002-01-11 NZ NZ526868A patent/NZ526868A/xx not_active IP Right Cessation
- 2002-01-11 AT AT02717325T patent/ATE361288T1/de active
- 2002-01-11 HU HU0302598A patent/HUP0302598A2/hu not_active IP Right Cessation
- 2002-01-11 IL IL15675102A patent/IL156751A0/xx unknown
- 2002-01-11 SI SI200230554T patent/SI1358184T1/sl unknown
- 2002-01-11 GE GE5315A patent/GEP20053692B/en unknown
- 2002-01-11 CZ CZ20031863A patent/CZ303356B6/cs not_active IP Right Cessation
- 2002-01-11 SK SK858-2003A patent/SK287860B6/sk not_active IP Right Cessation
- 2002-01-11 MX MXPA03006179A patent/MXPA03006179A/es active IP Right Grant
- 2002-01-11 RS YUP-605/03A patent/RS51477B/sr unknown
- 2002-01-11 ES ES02717325T patent/ES2284849T3/es not_active Expired - Lifetime
- 2002-01-11 EP EP07003413A patent/EP1798230A1/en not_active Withdrawn
- 2002-01-11 CN CNB028062027A patent/CN1313464C/zh not_active Expired - Fee Related
- 2002-01-11 DE DE60219887T patent/DE60219887T2/de not_active Expired - Lifetime
- 2002-01-11 CA CA002434277A patent/CA2434277C/en not_active Expired - Fee Related
- 2002-01-11 BR BR0206435-9A patent/BR0206435A/pt active Search and Examination
- 2002-01-11 DK DK02717325T patent/DK1358184T3/da active
- 2002-01-11 PL PL02368209A patent/PL368209A1/xx unknown
- 2002-01-11 EA EA200300788A patent/EA006973B1/ru not_active IP Right Cessation
- 2002-11-01 UA UA2003087598A patent/UA77167C2/uk unknown
-
2003
- 2003-07-02 IL IL156751A patent/IL156751A/en not_active IP Right Cessation
- 2003-07-03 IS IS6865A patent/IS2623B/is unknown
- 2003-07-11 NO NO20033181A patent/NO329306B1/no not_active IP Right Cessation
- 2003-07-21 BG BG108012A patent/BG66160B1/bg unknown
-
2005
- 2005-09-23 US US11/234,713 patent/US8058445B2/en not_active Expired - Lifetime
-
2006
- 2006-02-01 AU AU2006200437A patent/AU2006200437B2/en not_active Ceased
-
2007
- 2007-07-20 CY CY20071100969T patent/CY1106748T1/el unknown
-
2008
- 2008-09-01 IL IL193813A patent/IL193813A0/en not_active IP Right Cessation
- 2008-09-01 IL IL193814A patent/IL193814A/en not_active IP Right Cessation
-
2009
- 2009-04-13 JP JP2009097317A patent/JP2009286777A/ja active Pending
-
2011
- 2011-11-15 US US13/297,213 patent/US8642624B2/en not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/829,288 patent/US20130273004A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531484A5 (enExample) | ||
| JP2004527499A5 (enExample) | ||
| CA2434178A1 (en) | Substituted amine derivatives and methods of use | |
| JP2006502112A5 (enExample) | ||
| JP2004531473A5 (enExample) | ||
| AU2003252011B8 (en) | Substituted 2-alkylamine nicotinic amide derivatives and use there of | |
| JP2007504148A5 (enExample) | ||
| JP2009519967A5 (enExample) | ||
| CN101959516B (zh) | 用以治疗癌症的包含喹喔啉PI3Kα抑制剂的组合治疗 | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| JP4974438B2 (ja) | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体 | |
| EA006973B1 (ru) | Производные замещенных алкиламинов и их применение | |
| JP2013528591A5 (enExample) | ||
| RU2005136429A (ru) | Производные азаспироалканов в качестве тнгибиторов металлопротеаз | |
| JP2006520805A5 (enExample) | ||
| JP2020512343A5 (enExample) | ||
| JP2010529991A5 (enExample) | ||
| RU2004112191A (ru) | Лактамсодержащие соединения и их производные в качестве ингибиторов фактора ха | |
| JP2007503450A5 (enExample) | ||
| RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
| RU2003116649A (ru) | Гетероциклилэфирзамещенные имидазохинолины | |
| CA3051327A1 (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
| JP2008525502A5 (enExample) | ||
| JP2019537571A5 (enExample) | ||
| JP2021501145A5 (enExample) |